114 related articles for article (PubMed ID: 10948350)
21. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.
Gentile F; Tuszynski JA; Barakat KH
J Mol Graph Model; 2016 Apr; 65():71-82. PubMed ID: 26939044
[TBL] [Abstract][Full Text] [Related]
22. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins.
Jiang H; Yang LY
Cancer Res; 1999 Sep; 59(18):4529-34. PubMed ID: 10493501
[TBL] [Abstract][Full Text] [Related]
23. Xeroderma pigmentosum and molecular cloning of DNA repair genes.
Boulikas T
Anticancer Res; 1996; 16(2):693-708. PubMed ID: 8687116
[TBL] [Abstract][Full Text] [Related]
24. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC
Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192
[TBL] [Abstract][Full Text] [Related]
25. Regulation of DNA repair gene expression in human cancer cell lines.
McGurk CJ; Cummings M; Köberle B; Hartley JA; Oliver RT; Masters JR
J Cell Biochem; 2006 Apr; 97(5):1121-36. PubMed ID: 16315315
[TBL] [Abstract][Full Text] [Related]
26. Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer are not associated with XPA mutations or gene amplification.
States JC; Reed E
Cancer Lett; 1996 Nov; 108(2):233-7. PubMed ID: 8973600
[TBL] [Abstract][Full Text] [Related]
27. Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients.
Lai TC; Chow KC; Fang HY; Cho HC; Chen CY; Lin TY; Chiang IP; Ho SP
Oncol Rep; 2011 May; 25(5):1243-51. PubMed ID: 21327329
[TBL] [Abstract][Full Text] [Related]
28. Comparative analyses of relative ERCC3 and ERCC6 mRNA levels in gliomas and adjacent non-neoplastic brain.
Dabholkar MD; Berger MS; Vionnet JA; Overton L; Thompson C; Bostick-Bruton F; Yu JJ; Silber JR; Reed E
Mol Carcinog; 1996 Sep; 17(1):1-7. PubMed ID: 8876669
[TBL] [Abstract][Full Text] [Related]
29. Cyclosporin A inhibits nucleotide excision repair via downregulation of the xeroderma pigmentosum group A and G proteins, which is mediated by calcineurin inhibition.
Kuschal C; Thoms KM; Boeckmann L; Laspe P; Apel A; Schön MP; Emmert S
Exp Dermatol; 2011 Oct; 20(10):795-9. PubMed ID: 21707758
[TBL] [Abstract][Full Text] [Related]
30. Silibinin enhances the repair of ultraviolet B-induced DNA damage by activating p53-dependent nucleotide excision repair mechanism in human dermal fibroblasts.
Guillermo-Lagae R; Deep G; Ting H; Agarwal C; Agarwal R
Oncotarget; 2015 Nov; 6(37):39594-606. PubMed ID: 26447614
[TBL] [Abstract][Full Text] [Related]
31. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.
Wang QE; Milum K; Han C; Huang YW; Wani G; Thomale J; Wani AA
Mol Cancer; 2011 Mar; 10():24. PubMed ID: 21385444
[TBL] [Abstract][Full Text] [Related]
32. Decreased DNA repair gene expression among individuals exposed to arsenic in United States drinking water.
Andrew AS; Karagas MR; Hamilton JW
Int J Cancer; 2003 Apr; 104(3):263-8. PubMed ID: 12569548
[TBL] [Abstract][Full Text] [Related]
33. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
Darcy KM; Tian C; Reed E
Cancer Res; 2007 May; 67(9):4474-81. PubMed ID: 17483363
[TBL] [Abstract][Full Text] [Related]
34. Prognostic values of excision repair cross-complementing genes mRNA expression in ovarian cancer patients.
Zhao M; Li S; Zhou L; Shen Q; Zhu H; Zhu X
Life Sci; 2018 Feb; 194():34-39. PubMed ID: 29247747
[TBL] [Abstract][Full Text] [Related]
35. DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes.
Vogel U; Dybdahl M; Frentz G; Nexo BA
Mutat Res; 2000 Nov; 461(3):197-210. PubMed ID: 11056291
[TBL] [Abstract][Full Text] [Related]
36. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
Li QQ; Yunmbam MK; Zhong X; Yu JJ; Mimnaugh EG; Neckers L; Reed E
Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL61-72. PubMed ID: 11936875
[TBL] [Abstract][Full Text] [Related]
37. Nucleotide excision repair protein levels vis-à-vis anticancer drug resistance in 60 human tumor cell lines.
Chen ZP; Malapetsa A; Monks A; Myers TG; Mohr G; Sausville EA; Scudiero DA; Panasci LC
Ai Zheng; 2002 Mar; 21(3):233-9. PubMed ID: 12451985
[TBL] [Abstract][Full Text] [Related]
38. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932
[TBL] [Abstract][Full Text] [Related]
39. Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors.
Mimnaugh EG; Yunmbam MK; Li Q; Bonvini P; Hwang SG; Trepel J; Reed E; Neckers L
Biochem Pharmacol; 2000 Nov; 60(9):1343-54. PubMed ID: 11008128
[TBL] [Abstract][Full Text] [Related]
40. [ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs].
Bogush TA; Popova AS; Dudko EA; Bogush EA; Tyulyandina AS; Tyulyandin SA; Davydov MI
Antibiot Khimioter; 2015; 60(3-4):42-50. PubMed ID: 26415382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
